NYSE:ALife Sciences
How Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics
In late May and early June 2026, Agilent Technologies reported higher quarterly sales and earnings, raised its fiscal 2026 revenue guidance to US$7.39–US$7.49 billion, expanded FDA-approved use of its PD-L1 IHC 22C3 pharmDx diagnostic, launched several new lab software and instrument products, and announced an enterprise-wide AI collaboration with OpenAI and Boston Consulting Group.
Together, these moves highlight Agilent’s push to deepen its role in regulated lab workflows, broaden oncology...